Strengthening Ties: U.S.-Tunisia Cooperation in Science and Technology with Ambassador Joey R. Hood
BioTalk with Rich BendisShow Notes
In this episode of BioTalk with Rich Bendis, we have the honor of speaking with the U.S. Ambassador to the Republic of Tunisia, Joey R. Hood. With an impressive diplomacy and international relations background, Ambassador Hood sheds light on the vital collaboration between the U.S. and Tunisia in scientific research, innovation, and technology transfer. Host Rich Bendis is the President and CEO of BioHealth Innovation, Inc., dedicated to accelerating biohealth opportunities and fostering innovation across the BioHealth Capital Region of Maryland, Washington D.C., and Virginia….and the world.
Ambassador Hood discusses the current status of U.S.-Tunisia cooperation in scientific research and technology transfer, emphasizing these areas' critical role in Tunisia's development. He highlights the importance of scientific research, innovation, and technology transfer in Tunisia and explains how the U.S. can support and enhance these efforts.
We explore the Department of State-US funded CURES project in Tunisia, examining its goals, progress, and future objectives. Ambassador Hood elaborates on the significance of U.S. funding for projects like CURES and the broader impact on both nations. BioHealth Innovation, Inc. (BHI) is a contractor to FHI 360, supporting the CURES project to assist Tunisia in building its life science research, technology transfer, and commercialization capabilities.
The conversation also covers other key partnerships and projects that the U.S. supports in Tunisia, aimed at fostering research and technology transfer. Ambassador Hood shares insights into these collaborations and his vision for the future of U.S.-Tunisia relations in science and technology.
"The collaborative efforts between the U.S. and Tunisia in scientific research and technology transfer are crucial for advancing innovation and fostering economic growth. The programs we discuss on BioTalk are a testament to the great work happening in this field. I want to thank Ambassador Hood for joining us and sharing his invaluable insights on these important initiatives," says Rich Bendis.
About Joey R. Hood: Joey Hood was confirmed by the U.S. Senate on December 22, 2022. He has held several leadership positions in the U.S. Department of State's Bureau of Near Eastern Affairs, including Acting Assistant Secretary. His extensive diplomatic career includes assignments in Iraq, Kuwait, Saudi Arabia, Yemen, and Qatar. Prior to the Foreign Service, Mr. Hood was a Fulbright scholar in Burkina Faso and worked at a bank in Vermont. He earned a Master's degree from the Fletcher School at Tufts University and a Bachelor's degree from Dartmouth College.
Tune in to BioTalk for an insightful conversation with Ambassador Joey R. Hood as we explore the dynamics of U.S.-Tunisia cooperation in science and technology, and its potential to drive innovation and progress.
More from BioTalk with Rich Bendis
In this episode of BioTalk with Rich Bendis, Maureen L. Mulvihill, Ph.D., Founder, President, and CEO of Actuated Medical, discusses the company's 2026 BioHealth Capital Region Crab Trap Competition win and its work advancing medical device innovation from central Pennsylvania. Maureen shares how Actuated Medical grew from a focus on improving patient outcomes through innovative motion into a company with more than $50 million in non-dilutive funding, 43 patents, 9 FDA 510(k) clearances, and FDA-registered, ISO 13485-certified manufacturing infrastructure. Rich and Maureen also discuss the TubeClear system, Actuated Medical's first FDA-cleared device, including the story of the first patient it helped at Walter Reed, and how that experience shaped the company's mission. The episode also explores NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform, including how earlier work in tissue penetration led to brain implant technology, DARPA-supported commercialization, global research use, and the company's next steps toward clinical applications. Maureen also shares what comes next for Actuated Medical, including its focus on NeuroGlider, upcoming visibility at the MedTech Conference in Boston, and her advice to entrepreneurs building medical device companies: persistence matters. Editing and post-production work for this episode was provided by The Podcast Consultant. Maureen L. Mulvihill, Ph.D., is Founder, President, and CEO of Actuated Medical, a medical device company advancing the NeuralGlider® Precision Brain Access and Deep Brain Therapy Delivery Platform for neurotechnology, brain therapeutics, and longevity-related medicine. Under her leadership, Actuated Medical has secured more than $50 million in non-dilutive funding, developed a portfolio of 43 patents, achieved 9 FDA 510(k) clearances, and earned two SBA Tibbetts Awards recognizing excellence in commercialization. Dr. Mulvihill serves on the Board of Directors of AdvaMed, the AdvaMed Accel Board, the Life Sciences Pennsylvania Board of Directors, chairs the Industrial Advisory Board for the Penn State Center for Biodevices, and serves on the Kish Bank Regional Advisory Board. She has received more than 35 entrepreneurship and leadership awards, including being named 2020 Life Sciences Pennsylvania CEO of the Year and leading Actuated Medical to First Place in the 2026 BioHealth Capital Region Crab Trap Competition. She earned her Ph.D. from The Pennsylvania State University.
In this episode of BioTalk with Rich Bendis, Ralf Huss, MD, PhD, Managing Director and CEO of BioM Biotech Cluster Development GmbH and spokesperson for the Bavarian Biotechnology Cluster, joins the conversation to discuss Bavaria's biotechnology ecosystem and BioM's role in moving science toward commercialization. Ralf introduces BioM, the organization supporting biotech development in Munich and Bavaria for nearly 30 years, and shares how the cluster helps founders move from research ideas to company formation. The conversation touches on mentoring, boot camps, investor connections, entrepreneur-in-residence support, startup training, and physical incubation. Rich and Ralf also discuss the MAxL incubator, the m4 Award, and BioM's work with more than 250 startups. Ralf shares his perspective on what early-stage teams need most, why strong science alone is not enough, and how business leadership, IP, financing, market need, and the right commercialization path all play a role. The episode also explores emerging opportunities in biotech and medicine, including AI, digital medicine, quantum computing, nanotechnology, regenerative medicine, tech bio, and the growing convergence of biology, engineering, and advanced technologies. Ralf also discusses why international collaboration matters for regional biotech clusters and how Bavarian companies are thinking about U.S. partnerships, investors, market access, and connections to ecosystems like the BioHealth Capital Region. Editing and post-production work for this episode was provided by The Podcast Consultant. Ralf Huss, MD, PhD, is a physician-scientist, surgical pathologist, biotechnology executive, entrepreneur, and innovation leader with more than three decades of experience across academia, pharmaceutical research, biotechnology, digital pathology, regenerative medicine, and artificial intelligence in healthcare. He currently serves as Managing Director and CEO of BioM, the organization responsible for the development of the Bavarian Biotechnology Cluster, one of Europe's leading life science ecosystems. Throughout his career, he has held leadership positions in multinational pharmaceutical companies, venture-backed biotechnology firms, international academic research and medical centers, and innovation organizations, with a particular focus on translational medicine, cell and gene therapy, digital medicine, and AI-driven diagnostics. He has been awarded numerous honors and published more than 180 peer-reviewed articles, books, and book chapters.
In this episode of BioTalk with Rich Bendis, Subin Baral, Partner at Ernst & Young LLP and EY-Parthenon Global Life Sciences Deals Leader, joins the conversation to discuss the changing life sciences dealmaking environment and what it means for companies, investors, and regional innovation ecosystems.
In this episode of BioTalk with Rich Bendis, Tammi Thomas, President of TEDCO, joins the conversation to discuss how Maryland is helping entrepreneurs move ideas from research and concept to market.
In this episode of BioTalk with Rich Bendis, Matt Adams, Chief Executive Officer of BrainScope, joins the conversation to discuss how the Rockville-based company is working to bring objective brain function measurement into real-world clinical care.